Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
NCT00387738 · Dynavax Technologies Corporation · PHASE2 · terminated · last registry update 2019-04-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.” | – | Registry record, Dynavax Technologies Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-04Results posted on the registry: Charite University, Berlin, Germany, Levocetirizine Oral Tablet + Fexofenadine 60 Mg Oral Tablet (NCT01586091)
- 2019-09-27Also stopped (terminated): Sephoris Pharmaceuticals LLC, SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg + 2 capsules Ibuprofen and 1 placebo (NCT03332524)
- 2019-08-12Results posted on the registry: Organon and Co, Mometasone furoate nasal spray + Beclomethasone dipropionate nasal spray (NCT03879772)
- 2019-07-05Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 + Placebo (NCT02065336)
- 2019-05-31Results posted on the registry: NeXtGen Biologics, Inc., a drug against HRH1 (NCT03522675)
- 2019-04-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Rituximab + placebo (NCT03920722)
- 2019-04-16Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02738008)
- 2019-04-16Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02604212)
- 2019-04-16Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02604199)
- 2019-04-12Results posted on the registry: Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02577029)
- 2019-03-19Phase 3 first posted: Organon and Co, Mometasone furoate nasal spray + Beclomethasone dipropionate nasal spray (NCT03879772)
- 2019-03-11Results posted on the registry: Kaohsiung Veterans General Hospital., histamine-2 receptor antagonist + Placebo (NCT02418312)
- 2019-01-25Results posted on the registry: Nathan Kline Institute for Psychiatric Research, Betahistine + Placebo Oral Tablet (NCT00709202)
- 2018-12-12Also stopped (terminated): Bayer, Chlorpheniramine maleate (BAY X002134) + Placebo (NCT02722083)
- 2018-12-10Phase 3 first posted: Sherief Abd-Elsalam, Rupatadine + Montelukast (NCT03770923)
- 2018-10-18Phase 3 first posted: Apimeds, Inc., Apitox - pure honeybee toxin + Placebo (NCT03710655)
- 2018-09-25Results posted on the registry: Arrowhead Pharmaceuticals, ARC-521 Injection + antihistamine (NCT02797522)
- 2018-08-27Phase 3 first posted: Sherief Abd-Elsalam, CHOP + CHOP Plus Lanzoprazole (NCT03647072)
- 2018-08-16Results posted on the registry: Johns Hopkins University, a drug against HRH1 (NCT03509766)
- 2018-08-02Also stopped (terminated): Hong Kong Sanatorium & Hospital, a drug against HRH1 (NCT02047136)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision